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1. INTRODUCTION {#cas13912-sec-0001}
===============

The accident at Fukushima Dai‐ichi Nuclear Power Plant (NPP) occurred in March 2011 after the earthquake and tsunami in Japan, leading to a massive release of radionuclides into the environment. The amount of ^131^I from the Fukushima accident was about an order of magnitude lower than after the Chernobyl accident[1](#cas13912-bib-0001){ref-type="ref"}, [2](#cas13912-bib-0002){ref-type="ref"} and radiation doses to the thyroid in populations of affected regions, including children, were very low.[3](#cas13912-bib-0003){ref-type="ref"}, [4](#cas13912-bib-0004){ref-type="ref"} However, an uncertainty in potential exposure doses during the acute phase of the crisis in Fukushima and the experience of Chernobyl, after which a sharp increase in thyroid cancer incidence in children from the most affected regions was observed,[5](#cas13912-bib-0005){ref-type="ref"}, [6](#cas13912-bib-0006){ref-type="ref"}, [7](#cas13912-bib-0007){ref-type="ref"} led to the launch of the Fukushima Health Management Survey program.[8](#cas13912-bib-0008){ref-type="ref"} One of 4 detailed surveys, the Thyroid Ultrasound Examination (TUE) was started in October 2011.[9](#cas13912-bib-0009){ref-type="ref"} The aim of TUE was to undertake ultrasound screening of all children and adolescents of Fukushima Prefecture aged 18 years or younger as of April 1, 2011 (367 649 persons).

The first screening cycle, referred to as the "preliminary survey" was accomplished in March 2014, ie, 3 years after possible exposure to radiation, which would be insufficient for radiation effects on the thyroid (if any) to manifest, with the purpose to determine baseline thyroid disease incidence in the Prefecture. The second cycle, or the "first full‐scale survey," was carried out from April 2014 to March 2016; the third cycle, "second full‐scale survey," took place from May 2016 to March 2017, and currently the fourth cycle is in progress. The number of patients with malignant or suspected malignant nodules was 116 (among 300 473 examined), 71 (among 270 511), and 12 in the first, second, and third surveys, respectively.[10](#cas13912-bib-0010){ref-type="ref"}, [11](#cas13912-bib-0011){ref-type="ref"}, [12](#cas13912-bib-0012){ref-type="ref"} As of March 2016, of a total of 131 operated and pathologically confirmed thyroid cancer cases, 125 underwent surgery at Fukushima Medical University Hospital (Fukushima, Japan).[13](#cas13912-bib-0013){ref-type="ref"} Histopathologically, with a few exceptions, all cases of thyroid cancer in Fukushima were papillary thyroid carcinoma (PTC).

After Chernobyl, approximately 95% of thyroid malignancies were also PTC,[14](#cas13912-bib-0014){ref-type="ref"}, [15](#cas13912-bib-0015){ref-type="ref"}, [16](#cas13912-bib-0016){ref-type="ref"}, [17](#cas13912-bib-0017){ref-type="ref"} which displayed significant radiation dose‐dependent risk.[18](#cas13912-bib-0018){ref-type="ref"}, [19](#cas13912-bib-0019){ref-type="ref"} The increase in incidence of thyroid cancer in children was first registered in 1990, ie, 4 years after the accident,[5](#cas13912-bib-0005){ref-type="ref"}, [6](#cas13912-bib-0006){ref-type="ref"}, [7](#cas13912-bib-0007){ref-type="ref"} which is assumed to be the minimal period of latency after which radiation‐induced thyroid cancer can become detectable. Tumors diagnosed during the 1986‐1989 period are not considered to be related to radiation exposure.

From pathological studies, it is known that PTC detected 4‐5 years after the Chernobyl accident (tumors with the shortest latency) in Belarusian and Ukrainian children frequently had solid and solid‐follicular growth pattern, which is more characteristic for the youngest patients, whereas in the longer‐onset tumors the papillary structures were more common.[20](#cas13912-bib-0020){ref-type="ref"}, [21](#cas13912-bib-0021){ref-type="ref"}, [22](#cas13912-bib-0022){ref-type="ref"} The short‐latency PTCs were also morphologically more aggressive than tumors developing after a longer latency[20](#cas13912-bib-0020){ref-type="ref"}, [21](#cas13912-bib-0021){ref-type="ref"} or than sporadic PTC in age‐matched groups.[15](#cas13912-bib-0015){ref-type="ref"}, [22](#cas13912-bib-0022){ref-type="ref"}, [23](#cas13912-bib-0023){ref-type="ref"}

In view of morphological differences between radiation‐related and sporadic PTC in Chernobyl countries, and its temporal morphological evolution, the objectives of this study were to undertake detailed histopathological analyses of structural components and invasive characteristics of Fukushima PTC to determine whether time‐dependent changes could be seen in the whole group or age subgroups of operated patients, and to evaluate age‐related trends.

2. MATERIALS AND METHODS {#cas13912-sec-0002}
========================

2.1. Patients {#cas13912-sec-0003}
-------------

From 125 patients who underwent surgery at Fukushima Medical University Hospital, 119 cases of PTC were available for review by the authors TB, MI, and YH. Four cases (cribriform‐morular variant of PTC associated with familial adenomatous polyposis) were excluded from analysis, and the remaining 115 PTCs were included in the study. All paraffin sections of tumor and extratumoral tissues, as well as all paraffin sections of dissected lymph nodes stained with H&E for each case were reviewed.

The study was approved by the ethical committees of Fukushima Medical University nos. 1318, 1909, and 29195, which are guided by local policy, national law, and the World Medical Association Declaration of Helsinki. Written informed consent was obtained from all patients or their parents/guardians. Methods used were carried out in accordance with the approved guidelines.

2.2. Histopathology {#cas13912-sec-0004}
-------------------

Histological subtypes/variants of PTC were evaluated according to the 4th edition of the WHO histological classification of thyroid tumors.[24](#cas13912-bib-0024){ref-type="ref"} As this classifications indicates that classic (conventional) PTC also includes tumors with mixed structure, and the papillary architecture might not always overly present in those, PTCs under this study were additionally characterized according to the dominant growth pattern as papillary, follicular, and solid‐trabecular when the corresponding structure represented \>50% of tumor section. In our opinion, classification by the dominant structural component rather than by histological variant would be more useful here once the particularities of tumor architecture are being addressed.[16](#cas13912-bib-0016){ref-type="ref"}, [23](#cas13912-bib-0023){ref-type="ref"}, [25](#cas13912-bib-0025){ref-type="ref"}, [26](#cas13912-bib-0026){ref-type="ref"} Note that the distribution of the dominant growth patterns correlates but does not coincide with that of histological PTC variants, which are important for tumor prognostication and long‐term management (see Table [1](#cas13912-tbl-0001){ref-type="table"} for descriptive characteristics of cases in the study).

###### 

Descriptive clinicopathological characteristics of 115 cases of papillary thyroid carcinoma (PTC) detected after the nuclear accident of March 2011 in Fukushima, Japan

  Characteristics                                               Number or value                            \% or SD
  ------------------------------------------------------------- ------------------------------------------ --------------------------------------------
  Diagnosis time after accident                                                                            
  \<4 y                                                         78                                         67.8
  ≥4 y                                                          37                                         32.2
  Age (range), y                                                17.8 (9‐23)                                3.0[a](#cas13912-note-0002){ref-type="fn"}
  \<15                                                          15                                         13.0
  ≥15‐\<19                                                      44                                         38.3
  ≥19                                                           56                                         48.7
  Sex F/M (F:M ratio)                                           73/42 (1.7:1)                              63.5 (F)
  Tumor size (range), mm                                        14.8 (6‐51)                                8.7[a](#cas13912-note-0002){ref-type="fn"}
  ≤10                                                           35                                         30.4
  \>10‐≤20                                                      61                                         53.0
  \>20‐≤40                                                      17                                         14.8
  \>40                                                          2                                          1.7
  pT (7th edition)                                                                                         
  T1a                                                           20                                         17.4
  T1b                                                           41                                         35.7
  T2                                                            5                                          4.3
  T3                                                            49                                         42.6
  Histological variant[b](#cas13912-note-0020){ref-type="fn"}                                              
  Classic (conventional) papillary                              104                                        90.5
  Follicular                                                    5                                          4.3
  Solid                                                         4                                          3.5
  Diffuse sclerosing                                            2                                          1.7
  Dominant growth pattern                                                                                  
  Papillary                                                     81                                         70.5
  Follicular                                                    19                                         16.5
  Solid‐trabecular                                              15                                         13.0
  Complete tumor capsule                                        4[c](#cas13912-note-0200){ref-type="fn"}   3.5
  Oxyphilic changes                                             53                                         46.1
  Focal                                                         26                                         22.6
  Severe                                                        27                                         23.5
  Concomitant thyroid pathology                                 47                                         39.2
  Nodular                                                       10                                         8.7
  Diffuse                                                       35                                         30.4
  Chronic thyroiditis                                           33                                         28.7
  Intrathyroid spread                                           56                                         48.7
  Extrathyroidal extension                                      48                                         42.1
  Multifocality                                                 2                                          1.7
  Lymphatic/vascular invasion                                   84                                         73.0
  Lymph node metastasis                                         92                                         80.0
  N1a                                                           73                                         63.5
  N1b                                                           19                                         16.5
  Distant metastasis                                            3                                          2.6

Standard deviation.

The numbers are specified according to the 4th edition of the WHO histological classification of thyroid tumors[24](#cas13912-bib-0024){ref-type="ref"} and may slightly differ from those reported previously according to the 7th edition of the Japanese general rules for the description of thyroid cancer.[8](#cas13912-bib-0008){ref-type="ref"}, [13](#cas13912-bib-0013){ref-type="ref"}

All fully encapsulated PTCs were in adult patients aged ≥19 years at surgery

F, female; M, male.
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Oxyphilic cell metaplasia was evaluated as focal or severe. Tumor stage was determined according to the 7th edition of TNM classification system, which assigns minimal extrathyroidal extension to the fat and connective tissue to the pT3 category.[27](#cas13912-bib-0027){ref-type="ref"} Only marked intrathyroid spread to the lobe(s) was considered positive, including diffuse sclerosing variant (DSV)‐like spread. For clearer identification of lymphatic/vascular invasion, sections were stained histochemically (Van Gieson staining) to visualize elastic lamina, or immunohistochemically for CD34 (blood vessel endothelium) and D2‐40 (lymphatic vessel endothelium). Tumor invasiveness was defined as morphological evidence of intrathyroid spread, extrathyroidal extension, tumor multifocality, lymphatic/vascular invasion, or metastatic process, either alone or in combination.

All cases were divided into 2 main groups to be compared: those operated during the period less than 4 years after the Fukushima NPP accident and those operated 4‐5 years after the accident (78 and 37 cases, respectively). We further considered subgroups of patients according to their age at surgery: children (patients aged less than 15 years, 9 and 6 cases, respectively); adolescents (patients aged from 15 to less than 19 years, 29 and 15 cases, respectively; pediatric cases (children and adolescents combined, 38 and 21 cases, respectively); and adults (patients aged 19 years or more at surgery (40 and 16 cases, respectively). Analyses were carried out for all cases in the subgroups, and for partially and nonencapsulated tumors combined, as fully encapsulated PTC could display less pronounced invasive features.[14](#cas13912-bib-0014){ref-type="ref"}, [23](#cas13912-bib-0023){ref-type="ref"} Encapsulated tumors in this series were observed only in adult patients.

2.3. Statistical analysis {#cas13912-sec-0005}
-------------------------

Fisher\'s exact test for categorical data and Mann‐Whitney or Kruskal‐Wallis tests for quantitative measurements were used for univariate analysis. Multivariate logistic regression models were adjusted for age at surgery and sex. Analyses with very small numbers of outcomes (less than 5 per cell) or when quasi‐complete separation was observed were carried out using Firth\'s approach to bias‐reducing penalized maximum likelihood fit or exact logistic regression. Changes in characteristics across age groups were evaluated with the χ^2^ test (Cochran‐Armitage test) for trend for categorical and Jonckheere‐Terpstra test for quantitative data. Heterogeneity of age trends was evaluated using one degree of freedom likelihood ratio test for nested logistic regression models with and without an interaction term between onset indicator and age. Statistical assessments were undertaken using the 3.71 release of SAS Studio for the 9.4M5 version of SAS (SAS Institute, Cary, NC, USA) and/or IBM SPSS Statistics 24 software (IBM, Armonk, NY, USA). All tests were 2‐sided; *P *\<* *.05 was considered statistically significant.

3. RESULTS {#cas13912-sec-0006}
==========

3.1. Clinicopathological characteristics of the whole PTC series {#cas13912-sec-0007}
----------------------------------------------------------------

Mean age at surgery of patients diagnosed during the first 4 years after the Fukushima Dai‐ichi NPP accident (the earlier‐onset group) was 17.8 years, which was not different from the age of patients diagnosed later (the later‐onset group), 17.7 years old (Table [2](#cas13912-tbl-0002){ref-type="table"} and Figure [1](#cas13912-fig-0001){ref-type="fig"}). Most patients were female in both groups (61.5% and 67.6%, respectively); sex ratio did not vary significantly between the groups. Most tumors were nonencapsulated or partially encapsulated (111/115, 96.5%). Four fully encapsulated PTCs (3.5%) occurred in adult patients only in the earlier‐onset group.

###### 

Clinicopathological **c**haracteristics of papillary thyroid carcinomas PTCs detected by ultrasound screening during the first 4 years or later after the Fukushima Nuclear Power Plant accident, all age groups

  Period after the accident       \<4 y           ≥4 y       *P* value (uni)[a](#cas13912-note-0004){ref-type="fn"}   OR (95% CI)   *P* value (multi)[b](#cas13912-note-0005){ref-type="fn"}                         
  ------------------------------- --------------- ---------- -------------------------------------------------------- ------------- ---------------------------------------------------------- --------------------- ---------------------------------------------
  Number of cases                 78              67.8       37                                                       32.2                                                                                           
  Nonencapsulated                 74              64.3       37                                                       32.2                                                                                           
  Tumor capsule                   4               5.1        0                                                        0.0           .304                                                       0.21 (0.01‐5.71)      .356
  Sex (F:M ratio)                 48/30 (1.6:1)   61.5 (F)   25/12 (2.1:1)                                            67.6 (F)      .679                                                       1.28 (0.56‐2.92)      .551[c](#cas13912-note-0006){ref-type="fn"}
  Nonencapsulated (F:M ratio)     45/29 (1.6:1)   60.8 (F)   25/12 (2.1:1)                                            67.6 (F)      .537                                                       1.32 (0.58‐3.02)      .512
  Age, mean (range); years        17.8 (9‐22)     2.8        17.7 (10‐23)                                             3.4           .993                                                       0.99 (0.87‐1.13)      .859[d](#cas13912-note-0007){ref-type="fn"}
  Nonencapsulated                 17.7 (9‐22)     2.8        17.7 (10‐23)                                             3.4           .828                                                       1.00 (0.88‐1.14)      .982
  Tumor size, mean (range); mm    15.1 (6‐41)     8.2        14.2 (6‐51)                                              9.6           .188                                                       0.99 (0.94‐1.04)      .678
  Nonencapsulated                 15.1 (6‐41)     8.1        14.4 (6‐51)                                              9.6           .184                                                       0.99 (0.94‐1.04)      .695
  Tumor size ≤10 mm               22              28.2       13                                                       35.1          .517                                                       1.41 (0.60‐3.28)      .432
  Nonencapsulated                 21              28.4       13                                                       35.1          .516                                                       1.38 (0.59‐3.24)      .465
  Dominant growth pattern                                                                                                                                                                                            
  Papillary                       52              66.7       29                                                       78.4          .274                                                       1.82 (0.72‐4.56)      .204
  Nonencapsulated                 49              66.2       29                                                       78.4          .271                                                       1.85 (0.73‐4.67)      .194
  Follicular                      13              16.7       6                                                        16.2          1.000                                                      0.99 (0.34‐2.89)      .978
  Nonencapsulated                 13              17.6       6                                                        16.2          1.000                                                      0.95 (0.32‐2.77)      .917
  Solid‐trabecular                13              16.7       2                                                        5.4           .138                                                       0.33 (0.08‐1.42)      .137
  Nonencapsulated                 12              16.2       2                                                        5.4           .136                                                       0.33 (0.08‐1.44)      .141
  Oxyphilic changes                                                                                                                                                                                                  
  Focal                           18              23.1       8                                                        21.6          1.000                                                      0.93 (0.36‐2.39)      .884
  Nonencapsulated                 18              24.3       8                                                        21.6          .816                                                       0.88 (0.34‐2.26)      .787
  Severe                          20              25.6       7                                                        18.9          .488                                                       0.73 (0.28‐1.93)      .526
  Nonencapsulated                 19              25.7       7                                                        18.9          .484                                                       0.72 (0.27‐1.91)      .506
  Concomitant thyroid pathology                                                                                                                                                                                      
  Nodular                         8               10.3       2                                                        5.4           .497                                                       0.53 (0.11‐2.53)      .428
  Nonencapsulated                 8               10.8       2                                                        5.4           .491                                                       0.49 (0.10‐2.32)      .367
  Diffuse                         22              28.2       13                                                       35.1          .517                                                       1.31 (0.55‐3.13)      .542
  Nonencapsulated                 22              29.7       13                                                       35.1          .665                                                       1.22 (0.51‐2.92)      .657
  Chronic thyroiditis             20              25.6       13                                                       35.1          .378                                                       1.50 (0.61‐3.66)      .378
  Nonencapsulated                 20              27.0       13                                                       35.1          .388                                                       1.39 (0.57‐3.41)      .473
  Invasiveness                                                                                                                                                                                                       
  Intrathyroid spread             36              46.2       20                                                       54.1          .549                                                       1.39 (0.61‐3.17)      .427
  Nonencapsulated                 36              48.6       20                                                       54.1          .688                                                       1.28 (0.56‐2.91)      .556
  Extrathyroidal extension        34              43.6       14                                                       37.8          .687                                                       0.81 (0.36‐1.83)      .616
  Nonencapsulated                 34              45.9       14                                                       37.8          .542                                                       0.75 (0.33‐1.69)      .484
  Multifocality (Tm)              0               0.0        2                                                        5.4           .102                                                       11.35 (0.27‐479.24)   .116
  Nonencapsulated                 0               0.0        2                                                        5.4           .109                                                       10.86 (0.26‐459.06)   .122
  Lymphatic/vascular invasion     56              71.8       28                                                       75.7          .823                                                       1.7                   .754
  Nonencapsulated                 55              74.3       28                                                       75.7          1.000                                                      1.02 (0.41‐2.58)      .959
  Lymph node metastases (N1)      61              78.2       31                                                       83.8          .620                                                       1.53 (0.54‐4.34)      .427
  Nonencapsulated                 60              81.1       31                                                       83.8          .799                                                       1.30 (0.44‐3.82)      .636
  Distant metastases (M1)         3               3.8        0                                                        0.0           .550                                                       0.30 (0.01‐9.34)      .493
  Nonencapsulated                 3               4.1        0                                                        0.0           .549                                                       0.29 (0.01‐9.06)      .482

Univariate statistical tests.

Adjusted for sex and age unless otherwise specified.

Adjusted for age.

Adjusted for sex.

CI, confidence interval; F, female; M, male; OR, odds ratio.
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![Statistical comparison of the earlier‐ and later‐onset papillary thyroid carcinomas detected during thyroid ultrasound examinations of young individuals in Fukushima Prefecture following the nuclear accident of March 2011. All cases (ie, nonencapsulated, partially encapsulated, and fully encapsulated) are shown. Characteristics of the earlier‐onset tumors were used as a reference. Plotted are odds ratios and their 95% confidence intervals obtained in multivariate logistic regression analyses](CAS-110-817-g001){#cas13912-fig-0001}

Mean tumor size did not change significantly with time after the accident in the whole group (15.1 vs 14.2 mm, *P = *.678). The proportion of tumors sized 10.0 mm or more increased with time from 28.2% to 35.1% but statistical significance was not reached (*P = *.432). Of importance, Fukushima micro‐PTCs were not indolent microcarcinomas as both in the earlier‐ and later‐onset groups these tumors displayed extrathyroidal extension in 40.9% and 46.2% (*P = *1.000) and nodal disease in 77.3% and 92.3%, respectively (*P = *.377).

The distribution of dominant histological growth patterns did not show statistically significant changes over time, although a relative increase in the frequency of the papillary (from 66.7% to 78.4%, *P = *.204) and a decrease in the solid‐trabecular patterns (from 16.7% to 5.4%, *P = *.137) were seen. Among histological variants, the classic (conventional) PTC was the most prevalent (90.5% overall, Table [1](#cas13912-tbl-0001){ref-type="table"}) without significant differences between the earlier‐ and later‐onset groups (92.3% and 86.5%, respectively, *P = *.328). Histological variants such as follicular, solid, and DSV occurred in a minority cases.

Oxyphilic cell metaplasia was observed in 46.1% of cases cumulatively; no significant difference over time was detected (*P = *.884 and *P = *.526 for focal and severe changes, respectively, Table [2](#cas13912-tbl-0002){ref-type="table"}). Also, no differences between the 2 groups were observed for the presence of concomitant benign nodular thyroid pathology (10.3% vs 5.4%, *P = *.428) or chronic thyroiditis (25.6% vs 35.1%, *P = *.378).

Of importance, no differences in the frequencies of tumor invasive features such as intraglandular spread (*P = *.427), extrathyroidal extension (*P = *.616), lymphatic/vascular invasion (*P = *.754), and the presence of regional lymph node (*P = *.427) or distant metastases to the lung (*P = *.493) were found between the earlier‐ and later‐onset group (Figure [1](#cas13912-fig-0001){ref-type="fig"} and Table [2](#cas13912-tbl-0002){ref-type="table"}).

The results of analyses of partially/nonencapsulated tumors were similar to those obtained for the whole group. As for fully encapsulated tumors, 3 out of 4 PTCs showed dominant papillary growth pattern and tumor capsule invasion. Only 1 fully encapsulated PTC was noninvasive. This tumor, however, had dominant solid growth pattern with severe oxyphilic cell metaplasia, not meeting the criteria for a noninvasive follicular thyroid neoplasm with papillary‐like nuclear features.[24](#cas13912-bib-0024){ref-type="ref"}, [28](#cas13912-bib-0028){ref-type="ref"} The size of fully encapsulated PTCs ranged from 6.7 to 32.6 mm, mean 15.8 mm, which was not significantly different from the nonencapsulated tumors for the whole series (14.8 mm, *P = *.945) or for young adult patients (13.6 mm, *P = *.874). Only 1 encapsulated PTC with dominant papillary growth pattern, capsular and vascular invasion, and lymph node metastases was sized less than 10 mm.

3.2. Analysis in age subgroups {#cas13912-sec-0008}
------------------------------

Nearly identical results were obtained in separate analyses of age subgroups of children (Table [S1](#cas13912-sup-0002){ref-type="supplementary-material"}, Figure [S1](#cas13912-sup-0001){ref-type="supplementary-material"}), adolescents (Table [S2](#cas13912-sup-0003){ref-type="supplementary-material"}, Figure [S1](#cas13912-sup-0001){ref-type="supplementary-material"}), a combined children and adolescent group (the pediatric group, Table [S3](#cas13912-sup-0004){ref-type="supplementary-material"}, Figure [S1](#cas13912-sup-0001){ref-type="supplementary-material"}), and young adults (Table [S4](#cas13912-sup-0005){ref-type="supplementary-material"}, Figure [S1](#cas13912-sup-0001){ref-type="supplementary-material"}).

In the childhood subgroup (Table [S1](#cas13912-sup-0002){ref-type="supplementary-material"}), mean tumor size appeared to be greater in the later‐onset PTCs, although not statistically significantly (14.8 vs 22.0 mm, *P = *.430). A possible explanation is that 1 tumor removed 4 years after the accident was a DSV characterized by numerous small tumor foci scattered throughout the thyroid gland. Tumor size in this case is the size of the greatest thyroid lobe, which was 35 mm, contributing to the mean size increase.

In adolescents (Table [S2](#cas13912-sup-0003){ref-type="supplementary-material"}), a significant decrease in mean tumor size was observed over time on univariate (17.4 vs 11.2 mm, *P = *.007), but not on multivariate analysis (*P = *.061). This was paralleled by the greater frequency of small tumors sized 10 mm or less in the later‐onset PTCs (24.1% vs 60.0%, *P = *.026 on univariate and *P = *.059 on multivariate analysis, Table [S2](#cas13912-sup-0003){ref-type="supplementary-material"}), which remained marginally significant in the combined pediatric subgroup on multivariate analysis (*P = *.056, Table [S3](#cas13912-sup-0004){ref-type="supplementary-material"}).

In the adult subgroup, no significant changes in tumor size or frequency of small tumors were detected. The distribution of dominant growth patterns in adult patients displayed a tendency toward the increase in the frequency of tumors with dominant papillary structure and the decrease in the frequency of tumors with dominant solid‐trabecular patterns with time, which was seen on univariate statistical analysis but not in multivariate models (Table [S4](#cas13912-sup-0005){ref-type="supplementary-material"}).

No significant changes in the frequencies of oxyphilic cell metaplasia, any type of concomitant thyroid pathology and, importantly, of invasive features were found in any age subgroup (Tables [\[Link\]](#cas13912-sup-0002){ref-type="supplementary-material"}, [\[Link\]](#cas13912-sup-0003){ref-type="supplementary-material"}, [\[Link\]](#cas13912-sup-0004){ref-type="supplementary-material"}, Figure [S1](#cas13912-sup-0001){ref-type="supplementary-material"}).

3.3. Age‐related trends of histopathological characteristics of PTC {#cas13912-sec-0009}
-------------------------------------------------------------------

The availability of 3 age subgroups in the study enabled trend analysis. Several morphologic tumor characteristics were found to vary with age in the entire series, as well as in the earlier‐ and later‐onset groups (Table [3](#cas13912-tbl-0003){ref-type="table"}).

###### 

Age‐related trends for papillary thyroid carcinomas detected by ultrasound screening in Fukushima Prefecture, Japan, after the nuclear power plant accident

  Characteristics                 All cases   \<4 y                                      \>4 y      *P* heterogeneity                  
  ------------------------------- ----------- ------------------------------------------ ---------- ------------------- ---------- --- ----------
  Tumor capsule                   .063        ↑[a](#cas13912-note-0009){ref-type="fn"}   .073       ↑                   ND             ND
  Sex (F:M ratio)                 .778                                                   .979                           .717           .796
  Nonencapsulated                 .710                                                   .886                           .717           .845
  Tumor size, mean                **.024**    ↓[b](#cas13912-note-0010){ref-type="fn"}   **.026**   ↓                   .502           .751
  Nonencapsulated                 **.021**    ↓                                          **.026**   ↓                   .502           .766
  Tumor size ≤10 mm               .060        ↑                                          **.023**   ↑                   .819           .083
  Nonencapsulated                 .052        ↑                                          **.019**   ↑                   .819           .084
  Dominant growth pattern                                                                                                              
  Papillary                       .364                                                   0.562                          **.005**   ↑   **.034**
  Nonencapsulated                 .481                                                   .506                           **.005**   ↑   **.028**
  Follicular                      .088        ↓                                          .608                           **.027**   ↓   .291
  Nonencapsulated                 .217                                                   .744                           **.027**   ↓   .239
  Solid‐trabecular                .515                                                   .212                           .126           .174
  Nonencapsulated                 .671                                                   .233                           .126           .176
  Oxyphilic changes                                                                                                                    
  Focal                           .176                                                   .106                           .930           .432
  Nonencapsulated                 .244                                                   .164                           .930           .507
  Severe                          .171                                                   .441                           .227           .590
  Nonencapsulated                 .168                                                   .428                           .227           .597
  Concomitant thyroid pathology                                                                                                        
  Nodular                         .222                                                   .127                           .591           .201
  Nonencapsulated                 .210                                                   .096       ↑                   .591           .188
  Diffuse                         .062        ↓                                          **.036**   ↓                   .809           .313
  Nonencapsulated                 .101                                                   .065       ↓                   .809           .388
  Chronic thyroiditis             **.047**    ↓                                          **.025**   ↓                   .809           .268
  Nonencapsulated                 .077        ↓                                          .046       ↓                   .809           .333
  Invasiveness                                                                                                                         
  Intrathyroid spread             **.008**    ↓                                          **.006**   ↓                   .527           .332
  Nonencapsulated                 **.020**    ↓                                          **.017**   **↓**               .527           .421
  Extrathyroidal extension        .065        ↓                                          .245                           .102           .491
  Nonencapsulated                 .120                                                   .419                           .102           .386
  Multifocality (Tm)              .470                                                   ND^c^                          .591           ND
  Nonencapsulated                 .500                                                   ND                             .591           ND
  Lymphatic/vascular invasion     .238                                                   .235                           .766           .688
  Nonencapsulated                 .408                                                   .428                           .766           .838
  Lymph node metastases (N1)      .466                                                   .923                           .110           .288
  Nonencapsulated                 .199                                                   .636                           .110           .415
  Distant metastases (M1)         .374                                                   .309                           ND             .871
  Nonencapsulated                 .406                                                   .352                           ND             .901

An uptrend (frequency or value increases with age), indicated for *P* trend \<.1.

A downtrend (frequency or value decreases with age), indicated for *P* trend \<.1.

F, female; M, male; ND, not determined; values in bold indicate statistical significance.

John Wiley & Sons, Ltd

In the whole group, a statistically significant trend towards the decrease in mean tumor size (both all cases and nonencapsulated PTC) was seen (*P* ~trend~ = .024 and *P* ~trend~ = .021, respectively). Age‐related downtrends were also found for concomitant chronic thyroiditis (*P* ~trend~ = .047) and intrathyroid spread, whose frequency declined in all cases (*P* ~trend~ = .008) and nonencapsulated PTCs (*P* ~trend~ = .020). No significant age‐related trends were detected for other histopathological characteristics.

Among PTCs removed less than 4 years after the accident (earlier‐onset group), similar significant downtrends were observed for the above parameters. In addition, there was an uptrend for PTC sized 10 mm or more (both all cases and nonencapsulated, *P* ~trend~ = .023 and *P* ~trend~ = .019, respectively).

In the later‐onset group, significant age trends were observed only for the dominant growth patterns: an uptrend for dominant papillary (*P* ~trend~ = .005 for both all and nonencapsulated PTCs) and downtrend for dominant follicular growth patterns (*P* ~trend~ = .027 for both all and nonencapsulated PTCs).

Age‐related trends for most histopathological characteristics did not show heterogeneity between earlier‐ and later‐onset groups (Table [3](#cas13912-tbl-0003){ref-type="table"}). The increase in frequency of the dominant papillary growth pattern for all and nonencapsulated PTCs (*P* ~het~ = .034 and *P* ~het~ = .028, respectively) were the only trends that were more pronounced in the later‐ than in earlier‐onset PTC.

4. DISCUSSION {#cas13912-sec-0010}
=============

In this work, we examined temporal patterns of histopathological changes of Fukushima PTC bearing in mind that radiation‐related short‐latency PTC detected 4‐5 years after the Chernobyl accident was characterized by the high frequency of solid and solid‐follicular growth patterns and morphological features of higher aggressiveness in comparison with sporadic PTC in age‐matched groups.[15](#cas13912-bib-0015){ref-type="ref"}, [22](#cas13912-bib-0022){ref-type="ref"}, [23](#cas13912-bib-0023){ref-type="ref"}

Our analyses showed that most characteristics of PTC did not change significantly over time since the Fukushima NPP accident (see Figure [1](#cas13912-fig-0001){ref-type="fig"}). The only meaningful findings, complementing each other, were the decrease in tumor size and the increase in frequency of small PTCs measuring 10 mm or less in the later‐onset tumors in adolescents, seen on univariate statistical analysis. Similar changes, however, were not observed in childhood or in adult patients' subgroups.

An increase in the frequency of micro‐PTCs after repeated screening examination has been reported in the Belarusian‐American and Ukrainian‐American Chernobyl cohorts,[25](#cas13912-bib-0025){ref-type="ref"}, [29](#cas13912-bib-0029){ref-type="ref"} ascribed to active health surveillance. In our opinion, a somewhat increased detection rate of small‐size tumors in Fukushima TUE in adolescents in the later‐onset group could also be explained, at least in part, by the repeated screening. Further screenings will probably shed light if similar changes would be seen in other age subgroups.

It is important to emphasize that micro‐PTCs in this study were not incidental "occult" tumors just because they were detected by ultrasound in asymptomatic patients. The high rates of extrathyroidal extension to the fat and connective tissue and nodal disease attest to the justified treatment tactics that included surgery in view of the patients' young age and the risk of rapid progression of tumors with such invasive characteristics.[30](#cas13912-bib-0030){ref-type="ref"}, [31](#cas13912-bib-0031){ref-type="ref"}, [32](#cas13912-bib-0032){ref-type="ref"}, [33](#cas13912-bib-0033){ref-type="ref"}

It should be noted that in 2017, the criteria for ascribing well‐differentiated thyroid carcinomas pT3 category were revised in the 8th edition of the TNM classification.[34](#cas13912-bib-0034){ref-type="ref"} According to this classification, tumors larger than 40 mm confined to the thyroid belong to the pT3a category. The new pT3b category includes tumors of any size, but only if there are signs of tumor extension to the muscle surrounding the thyroid. In the series under study, no tumors extending to the muscle (pT3b = 0) and only 2 PTCs larger than 40 mm (pT3a = 2, tumors sized 40.5 and 51 mm) were observed. Consequently, if the 8th edition of the TNM classification was applied, 47 out of 49 PTCs would migrate from the pT3 to pT1a, pT1b, and pT2 categories. However, in our opinion, even the minimal extrathyroidal extension deserved attention in the analysis of PTC invasiveness undertaken in this study.

We did not observe significant changes in mean tumor size in the whole series, which was 15.1 and 14.2 mm in the earlier‐ and later‐onset PTC. Noteworthy nevertheless, that it was substantially smaller than that of sporadic PTCs from young patients from Japan. In previous studies, mean tumor size was 25.0 mm in children younger than 15 years at operation, and 18.0 mm in adolescents aged 15 years or older at surgery.[35](#cas13912-bib-0035){ref-type="ref"} Another study reported sizes of 24.0 mm in children younger than 15 years at surgery and 21.9 mm in adolescents aged 15‐18 years at surgery.[26](#cas13912-bib-0026){ref-type="ref"} We explain these observations by the screening in Fukushima as all previous works involved tumors from nonscreened individuals. In addition, it appears that before the NPP accident, thyroid cancers in young patients were usually detected at a more advanced stage. In this regard, a comparative histopathological analysis of Fukushima PTC and age‐matched sporadic PTC from Japan would be useful.

Mean tumor size tended to decrease with age in patients from Fukushima (see Table [3](#cas13912-tbl-0003){ref-type="table"}). In our previous study of mutational profile of Fukushima PTC, the most prevalent *BRAF* ^*V600E*^ mutation (found in 63.2% of cases) was positively correlated with patients' age, ie, displaying an increase in prevalence from children to adults.[36](#cas13912-bib-0036){ref-type="ref"}, [37](#cas13912-bib-0037){ref-type="ref"} Furthermore, *BRAF* ^*V600E*^ was significantly associated with a smaller tumor size and a higher chance of occurring in micro‐PTC. On the contrary, gene rearrangements (combined with unknown genetic alteration) were more prevalent in the tumors of younger patients and associated with larger tumor size. These observations underscore age‐related difference in the molecular pathogenesis of PTC and indicate that *BRAF* ^*V600E*^‐positive tumors might grow more slowly than those harboring other types of activated oncogenes (or even stop growing). Future molecular analysis, currently underway, is expected to reveal whether there is a shift from point mutations to gene rearrangements in the tumors operated 4‐5 years and on after the accident if a scenario of radiation‐related carcinogenesis similar to that in Chernobyl would be taking place. According to our histopathological analysis, however, the frequency of PTCs with the dominant papillary growth pattern remained prevalent in all subgroups regardless of time since the accident. It was even increased in young adults who underwent surgery 4‐5 years after the accident, whereas the frequency of tumors with the solid‐trabecular structure decreased (Table [S4](#cas13912-sup-0005){ref-type="supplementary-material"}) in contrast to Chernobyl PTCs. These observations suggest that the "radiation nature" of later‐onset tumors in Fukushima residents would be unlikely.

Morphological features of tumor aggressiveness, such as intrathyroid spread, extrathyroidal extension, lymphatic/vascular invasion, and frequency of regional lymph node metastases, did not change in the whole series or in age‐matched subgroups. This is also at variance with findings in Chernobyl, where a significant difference in tumor aggressiveness was seen between radiation‐related and sporadic PTC in age‐matched groups.[15](#cas13912-bib-0015){ref-type="ref"}, [22](#cas13912-bib-0022){ref-type="ref"} These facts again advocate a similar etiology of the earlier‐ and later‐onset PTC in Fukushima.

Our analysis of age trends detected a significant decrease in the frequency of intrathyroid spread (in all PTCs and earlier‐onset group). In general, tumor aggressiveness at presentation is known to decline with patients' age, both in radiogenic and sporadic PTC.[22](#cas13912-bib-0022){ref-type="ref"}, [23](#cas13912-bib-0023){ref-type="ref"} This might point at the common mechanisms underlying lesser tumor aggressiveness in older patients regardless of etiology; these may involve, eg, difference from younger patients' spectrum of somatic mutations driving carcinogenesis.

We acknowledge that our study has some limitations, primarily due to the inherent characteristics of the studied group of patients. In particular, the group of children included a small number of subjects. Furthermore, while the number of childhood cases in the later‐onset group could increase (3 additional patients aged less than 15 years were diagnosed in the second full‐scale survey),[12](#cas13912-bib-0012){ref-type="ref"} the number of earlier‐onset tumors will not. The same consideration applies to all other age subgroups described in the study. This circumstance, however, does not impede statistical analysis, although due to insufficient statistical power some subtle changes, perhaps, could not be revealed. However, our results show that no strong effects corresponding to morphological changes could be expected on comparison of the earlier‐ and later‐onset tumors either in individual age subgroups or in the combined pediatric or the whole group.

In conclusion, our study shows that PTCs detected in Fukushima Prefecture during mass ultrasound thyroid screening of young individuals do not display specific qualitative changes in tumor histopathology or morphological features of tumor aggressiveness over time. The similarity of pathological characteristics between tumors removed within 4 years after the Fukushima Dai‐ichi NPP accident and 4‐5 years after it strongly suggests their common etiology, which is unlikely related to radiation.
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